Eqis Capital Management Inc. Grows Stake in Bristol-Myers Squibb Co (NYSE:BMY)

Share on StockTwits

Eqis Capital Management Inc. grew its position in Bristol-Myers Squibb Co (NYSE:BMY) by 20.2% during the 3rd quarter, Holdings Channel.com reports. The firm owned 65,429 shares of the biopharmaceutical company’s stock after purchasing an additional 11,002 shares during the period. Eqis Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $3,318,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nuveen Asset Management LLC grew its holdings in shares of Bristol-Myers Squibb by 14,860.1% during the second quarter. Nuveen Asset Management LLC now owns 9,395,120 shares of the biopharmaceutical company’s stock valued at $426,069,000 after buying an additional 9,332,319 shares during the last quarter. Baupost Group LLC MA raised its position in shares of Bristol-Myers Squibb by 225.0% in the second quarter. Baupost Group LLC MA now owns 13,000,000 shares of the biopharmaceutical company’s stock worth $589,550,000 after acquiring an additional 9,000,000 shares during the period. Renaissance Technologies LLC raised its position in shares of Bristol-Myers Squibb by 67.6% during the 2nd quarter. Renaissance Technologies LLC now owns 20,698,607 shares of the biopharmaceutical company’s stock worth $938,682,000 after purchasing an additional 8,347,432 shares during the last quarter. BlackRock Inc. raised its position in shares of Bristol-Myers Squibb by 6.7% during the 2nd quarter. BlackRock Inc. now owns 114,798,394 shares of the biopharmaceutical company’s stock worth $5,206,108,000 after purchasing an additional 7,178,698 shares during the last quarter. Finally, Janus Henderson Group PLC raised its position in shares of Bristol-Myers Squibb by 75.7% during the 2nd quarter. Janus Henderson Group PLC now owns 16,156,559 shares of the biopharmaceutical company’s stock worth $732,691,000 after purchasing an additional 6,960,047 shares during the last quarter. 80.90% of the stock is currently owned by institutional investors and hedge funds.

In other news, SVP John E. Elicker sold 15,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total value of $849,900.00. Following the completion of the sale, the senior vice president now owns 74,471 shares of the company’s stock, valued at approximately $4,219,526.86. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Louis S. Schmukler sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the completion of the sale, the insider now directly owns 31,963 shares of the company’s stock, valued at approximately $1,807,827.28. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by corporate insiders.

NYSE BMY traded up $0.59 during trading hours on Tuesday, hitting $58.74. 1,399,899 shares of the company’s stock traded hands, compared to its average volume of 13,093,408. Bristol-Myers Squibb Co has a 52-week low of $42.48 and a 52-week high of $58.46. The company has a market capitalization of $94.53 billion, a PE ratio of 14.76, a PEG ratio of 1.35 and a beta of 0.71. The company has a debt-to-equity ratio of 1.37, a current ratio of 3.83 and a quick ratio of 3.72. The firm’s 50-day moving average is $53.20 and its 200-day moving average is $48.32.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The company had revenue of $6.01 billion during the quarter, compared to analysts’ expectations of $5.89 billion. During the same quarter in the prior year, the company earned $1.09 EPS. Bristol-Myers Squibb’s revenue was up 5.6% compared to the same quarter last year. Equities research analysts predict that Bristol-Myers Squibb Co will post 4.33 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were paid a dividend of $0.41 per share. The ex-dividend date was Thursday, October 3rd. This represents a $1.64 annualized dividend and a yield of 2.79%. Bristol-Myers Squibb’s dividend payout ratio is presently 41.21%.

BMY has been the subject of several research analyst reports. TheStreet upgraded shares of Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. set a $62.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Friday, September 13th. Peel Hunt restated a “buy” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, October 29th. UBS Group upped their price target on shares of Bristol-Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 23rd. Finally, ValuEngine downgraded shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $56.64.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Story: Net Margin

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.